Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2004
Newron Pharmaceuticals’ Consortium Gains EU Funding for Development of ION Channel Drug Screening Systems01/12/2004 | 
ENG
| 
ITA
| |
Newron announces positive results with ralfinamide from Phase II trial in neuropathic pain26/10/2004 |
ENG
|
ITA
| |
Dynogen licenses compounds from Newron for Genitourinary and Gastrointestinal disorders12/10/2004 |
ENG
| ||
Newron initiates Parkinson's disease Phase III trial with Safinamide13/09/2004 |
ENG
|
ITA
| |
Newron Pharmaceuticals Appoints Rolf Stahel as Chairman. Former CEO of Shire Pharmaceuticals Brings Extensive Experience in Building Pharmaceutical Companies30/06/2004 |
ENG
|
ITA
| |
Newron and Zambon Group Sign Collaboration to Develop Novel Treatments for Pain Conditions06/05/2004 |
ENG
|
ITA
|